Why is West Pharmaceutical Services, Inc. stock rising?
West raised its FY2026 guidance to 10%-11% organic revenue growth and $8.85-$9.05 adjusted EPS, citing stronger non-GLP-1 HVP components and HVP delivery devices.
Annex 1-related HVP upgrades are expected to contribute 200 basis points to 2026 revenue growth, with management seeing potential for the program to expand further.
Dublin West Vantage drug-handling revenue is expected to reach about $20 million in 2026, with a real step-up in Q4 and further ramp into 2027.
West expects to participate in international generic GLP-1 launches by supplying high-value elastomer components, including stoppers, plungers and line seals.
West is expanding the Eschweiler operational-excellence playbook across all HVP sites to increase throughput on existing assets during 2026.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for West Pharmaceutical Services, Inc. and 4,900+ companies.